Study Comparing Limited and Extensive Neck Surgery in Oral Cancer Patients With Neck Spread (ExtentN1)
Extent of Neck Treatment in Clinically N1 Oral Cancer: A Randomized Controlled Trial
Oral cavity squamous cell carcinoma (OCSCC) frequently metastasizes to cervical lymph nodes, and the extent of neck dissection remains an area of ongoing debate in patients with clinically node-positive (cN1) disease. While modified neck dissection (MND, levels I-V) is widely practiced, selective neck dissection (SND, levels I-IV) may provide equivalent oncologic outcomes with reduced surgical morbidity. However, high-quality randomized evidence comparing these approaches is lacking.
The ExteNT N1 Trial is a prospective, randomized, open-label, parallel-group clinical trial designed to compare selective neck dissection (levels I-IV) with modified neck dissection (levels I-V, preserving the spinal accessory nerve, internal jugular vein, and sternocleidomastoid muscle) in patients with resectable cN1 oral cavity squamous cell carcinoma. Eligible participants will be randomized in a 1:1 ratio to either treatment arm.
The primary endpoint is 3-year regional recurrence-free survival (RRFS), along with postoperative quality of life measured using the Neck Dissection Impairment Index (NDII). Secondary endpoints include overall survival, disease-free survival, level-wise nodal involvement, nodal yield, shoulder function (Constant-Murley Score, SPADI, and Arm Abduction Score), postoperative complications including chyle leak, and other surgical morbidities.
This trial aims to generate level I evidence regarding the optimal extent of neck dissection for cN1 OCSCC, balancing oncologic safety with preservation of postoperative function and quality of life.
研究概览
地位
条件
详细说明
Cervical lymph node metastasis is the most important prognostic factor in oral cavity squamous cell carcinoma (OCSCC). Surgical management of the neck is an integral component of treatment; however, the optimal extent of neck dissection for patients with clinically node-positive (cN1) disease remains uncertain. Although modified neck dissection (levels I-V with preservation of non-lymphatic structures) has traditionally been recommended for node-positive disease, several retrospective studies have suggested that carefully selected patients with limited nodal disease may achieve comparable regional control with a less extensive selective neck dissection. Nevertheless, these studies are subject to selection bias, and no adequately powered randomized controlled trial has directly compared these surgical approaches.
Dissection of lower cervical nodal levels may increase operative time and postoperative morbidity, including shoulder dysfunction, sensory deficits, chyle leak, and impairment in quality of life. Reducing the extent of neck dissection without compromising oncologic outcomes could improve postoperative functional recovery and patient-reported outcomes while maintaining regional disease control.
The ExteNT N1 Trial is designed to address this evidence gap by comparing selective neck dissection (levels I-IV) with modified neck dissection (levels I-V) in patients with resectable cN1 OCSCC. In addition to evaluating oncologic outcomes, the study incorporates validated functional and quality-of-life assessments to comprehensively evaluate the impact of the two surgical strategies. Participants will receive standard treatment for the primary tumor, and adjuvant therapy will be administered according to final histopathological findings and contemporary treatment guidelines.
The findings of this trial are expected to provide high-level evidence to guide the surgical management of the clinically N1 neck in OCSCC. If selective neck dissection demonstrates equivalent oncologic outcomes with lower morbidity, it may support a change in surgical practice by reducing unnecessary treatment while preserving function and quality of life.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名：Maroti B Wadewale, MDS, FHNO
- 电话号码：+918483851334
- 邮箱：dr.marotiwadewale59@gmail.com
研究联系人备份
- 姓名：Parag J Watve, MS, FHNS
- 电话号码：+919823109918
- 邮箱：paragwatve@kolhapurcancercentre.com
学习地点
-
-
Maharashtra
-
Kolhāpur、Maharashtra、印度、416004
- 招聘中
- Kolhapur Cancer Centre
-
接触：
- Maroti B Wadewale, MDS, FHNO
- 电话号码：+918483851334
- 邮箱：dr.marotiwadewale59@gmail.com
-
接触：
- Yogesh Anap, MD
- 电话号码：+919867155930
- 邮箱：yogesh.anap1@gmail.com
-
首席研究员：
- Maroti B Wadewale, MDS, FHNO
-
副研究员：
- Parag Watve, MS, FHNS
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Histologically proven squamous cell carcinoma of oral cavity will be included
- Clinical stage T1-T4, N1, M0
- cN1 neck on clinical examination and imaging (CT/MRI)
- Single node which is FNAC proven without any other significant nodes.
- Patients with ASA grade II and I.
- Understands the protocol and able to give informed consent.
Exclusion Criteria:
- Recurrent cases
- Multiple significant nodes
- Nodes clinical/radiological with ENE
- Single metastatic node at level III/IV/V
- Single metastatic node with other suspicious nodes
- Patients with a history of head and neck radiation therapy treatment
- Previous history of any malignancy
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Arm 1- Selective neck dissection level I to level IV
Participants randomized to this arm will undergo surgical resection of the primary oral cavity squamous cell carcinoma along with ipsilateral selective neck dissection involving cervical lymph node levels I-IV.
Contralateral neck management, reconstruction, and adjuvant therapy will be performed according to standard institutional protocols and final histopathological findings.
|
Selective neck dissection will include removal of cervical lymph node levels Ia, Ib, IIa, IIb, III, and IV on the ipsilateral side while preserving uninvolved non-lymphatic structures.
The primary oral cavity tumor will be resected according to oncologic principles with reconstruction as required.
Contralateral neck management and adjuvant therapy will be provided according to institutional protocols and final histopathological findings.
|
|
有源比较器：Arm 2- Modified Neck Dissection (Levels I-V)
Participants randomized to this arm will undergo surgical resection of the primary oral cavity squamous cell carcinoma along with ipsilateral modified neck dissection involving cervical lymph node levels I-V while preserving the spinal accessory nerve, internal jugular vein, and sternocleidomastoid muscle whenever oncologically appropriate.
Contralateral neck management, reconstruction, and adjuvant therapy will be performed according to standard institutional protocols and final histopathological findings.
|
Modified neck dissection will include removal of cervical lymph node levels Ia, Ib, IIa, IIb, III, IV, and V on the ipsilateral side while preserving the spinal accessory nerve, internal jugular vein, and sternocleidomastoid muscle whenever oncologically appropriate.
The primary oral cavity tumor will be resected according to oncologic principles with reconstruction as required.
Contralateral neck management and adjuvant therapy will be provided according to institutional protocols and final histopathological findings.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Regional Recurrence-Free Survival (RRFS)
大体时间：3 years after surgery
|
Regional recurrence-free survival is defined as the time from the date of definitive surgery to the first documented regional recurrence in the cervical lymph nodes or death from any cause, whichever occurs first.
Regional recurrence will be confirmed by clinical examination, imaging, and histopathological evaluation whenever feasible.
|
3 years after surgery
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival (OS)
大体时间：Up to 3 years after surgery
|
Overall survival is defined as the time from definitive surgery until death from any cause.
|
Up to 3 years after surgery
|
|
Disease-Free Survival (DFS)
大体时间：Up to 3 years after surgery
|
Disease-free survival is defined as the time from definitive surgery to the first documented local, regional, or distant recurrence, or death from any cause.
|
Up to 3 years after surgery
|
|
Level-wise Cervical Lymph Node Metastasis
大体时间：At the time of surgery (histopathological examination)
|
Distribution of histopathologically confirmed metastatic lymph nodes according to cervical nodal level.
|
At the time of surgery (histopathological examination)
|
|
Nodal Yield
大体时间：At the time of surgery
|
Total number of lymph nodes retrieved during neck dissection and confirmed by histopathological examination.
|
At the time of surgery
|
|
Shoulder Function assesment
大体时间：Preoperatively; 1 month; 3 months; 6 months, 1 and 2 year
|
Shoulder function will be assessed using the Constant-Murley Score (0-100 points), with higher scores indicating better shoulder function.
|
Preoperatively; 1 month; 3 months; 6 months, 1 and 2 year
|
|
Postoperative Surgical Morbidity
大体时间：Within 30 days after surgery
|
Incidence of postoperative complications, including chyle leak, hematoma, wound infection, seroma, cranial nerve injury
|
Within 30 days after surgery
|
|
Shoulder function assesment with Shoulder pain and disability index
大体时间：Preoperatively; 1 week; 1 month; 3 months; 6 months; 1 year; and 2 years after surgery
|
Shoulder pain and disability will be assessed using theShoulder pain and disability index questionnaire.
Scores range from 0 to 100, with higher scores indicating greater pain and disability.
|
Preoperatively; 1 week; 1 month; 3 months; 6 months; 1 year; and 2 years after surgery
|
合作者和调查者
出版物和有用的链接
一般刊物
- Pantvaidya GH, Pal P, Vaidya AD, Pai PS, D'Cruz AK. Prospective study of 583 neck dissections in oral cancers: implications for clinical practice. Head Neck. 2014 Oct;36(10):1503-7. doi: 10.1002/hed.23494. Epub 2014 Jan 13.
- Liang L, Zhang T, Kong Q, Liang J, Liao G. A meta-analysis on selective versus comprehensive neck dissection in oral squamous cell carcinoma patients with clinically node-positive neck. Oral Oncol. 2015 Dec;51(12):1076-81. doi: 10.1016/j.oraloncology.2015.10.005. Epub 2015 Oct 23.
- Hashmi SS, Abbas A, Bukhari A, Saeed J, Shafqat A, Siddique AH, Buksh AR, Murtaza G. Selective Neck Dissection for Node-Positive Oral Cavity Squamous Cell Carcinoma: A Retrospective Cohort Study. Int Arch Otorhinolaryngol. 2022 Feb 22;26(4):e630-e635. doi: 10.1055/s-0041-1741437. eCollection 2022 Oct.
- Shin YS, Koh YW, Kim SH, Choi EC. Selective neck dissection for clinically node-positive oral cavity squamous cell carcinoma. Yonsei Med J. 2013 Jan 1;54(1):139-44. doi: 10.3349/ymj.2013.54.1.139.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- ExteNTN1
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.